Clinical trial
Analysis of Ibrutinib Efficacy and Safety in the Treatment of Chronic Lymphocytic Leukemia Patients in Routine Clinical Practice
NCT03633045 is registered in ClinicalTrials.gov with Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Analysis of Ibrutinib Efficacy and Safety in the Treatment of Chronic Lymphocytic Leukemia Patients in Routine Clinical Practice
- Lead sponsor
- Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- September 1, 2018
- Completion date
- April 30, 2022
- Enrollment
- 70 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
chronic lymphocytic leukemia